Correction: Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer (Oncotarget (2016) 7 (76920-76933) DOI: 10.18632/oncotarget.12729);Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer

Oncotarget

Volumn 7, Issue 47, 2016, Pages 76920-76933

  Escudero Esparza, Astrid ^a   Bartoschek, Michael ^b   Gialeli, Chrysostomi ^a   Okroj, Marcin ^c   Owen, Sioned ^d   Jirström, Karin ^e   Orimo, Akira ^f   Jiang, Wen G ^d   Pietras, Kristian ^b   Blom, Anna M ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^e LUND UNIVERSITY   (Sweden)

^f JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Complement system; CSMD1; Invasion; Tumor suppressor

Indexed keywords

ALDEHYDE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; GLYCOGEN SYNTHASE KINASE 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; STAT2 PROTEIN; CSMD1 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CLONOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; CSMD1 GENE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN PHOSPHORYLATION; SURVIVAL PREDICTION; SURVIVAL TIME; TUMOR ESCAPE; TUMOR SUPPRESSOR GENE; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CELL MOTION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MICE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84999053484     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.28426     Document Type: Erratum

References (35)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
2. Sherr CJ. Principles of tumor suppression. Cell. 2004; 116:235-246.
3. Escudero-Esparza A, Kalchishkova N, Kurbasic E, Jiang WG, Blom AM. The novel complement inhibitor human CUB, Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly. FASEB J. 2013; 27:5083-5093.
4. Tang MR, Wang YX, Guo S, Han SY, Wang D. CSMD1 exhibits antitumor activity in A375 melanoma cells through activation of the Smad pathway. Apoptosis. 2012; 17:927-937.
5. Sun PC, Uppaluri R, Schmidt AP, Pashia ME, Quant EC, Sunwoo JB, Gollin SM, Scholnick SB. Transcript map of the 8p23 putative tumor suppressor region. Genomics. 2001; 75:17-25.
6. Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, et al. Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther. 2009; 8:907-916.
7. Kamal M, Shaaban AM, Zhang L, Walker C, Gray S, Thakker N, Toomes C, Speirs V, Bell SM. Loss of CSMD1 expression is associated with high tumor grade and poor survival in invasive ductal breast carcinoma. Breast Cancer Res Treat. 2010; 121:555-563.
8. Scholnick SB, Richter TM. The role of CSMD1 in head and neck carcinogenesis. Genes Chromosomes Cancer. 2003; 38:281-283.
9. Toomes C, Jackson A, Maguire K, Wood J, Gollin S, Ishwad C, Paterson I, Prime S, Parkinson K, Bell S, Woods G, Markham A, Oliver R, et al. The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis. Genes Chromosomes Cancer. 2003; 37:132-140.
10. Beuten J, Gelfond JA, Martinez-Fierro ML, Weldon KS, Crandall AC, Rojas-Martinez A, Thompson IM, Leach RJ. Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men. Carcinogenesis. 2009; 30:1372-1379.
11. Farrell C, Crimm H, Meeh P, Croshaw R, Barbar T, Vandersteenhoven JJ, Butler W, Buckhaults P. Somatic mutations to CSMD1 in colorectal adenocarcinomas. Cancer Biol Ther. 2008; 7:609-613.
12. Shull AY, Clendenning ML, Ghoshal-Gupta S, Farrell CL, Vangapandu HV, Dudas L, Wilkerson BJ, Buckhaults PJ. Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients. PloS one. 2013; 8:e58731.
13. Zhang R, Song C. Loss of CSMD1 or 2 may contribute to the poor prognosis of colorectal cancer patients. Tumour Biol. 2014; 35:4419-4423.
14. Midorikawa Y, Yamamoto S, Tsuji S, Kamimura N, Ishikawa S, Igarashi H, Makuuchi M, Kokudo N, Sugimura H, Aburatani H. Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis. Hepatology. 2009; 49:513-522.
15. Richter TM, Tong BD, Scholnick SB. Epigenetic inactivation and aberrant transcription of CSMD1 in squamous cell carcinoma cell lines. Cancer Cell Int. 2005; 5:29.
16. Scholnick SB, Haughey BH, Sunwoo JB, el-Mofty SK, Baty JD, Piccirillo JF, Zequeira MR. Chromosome 8 allelic loss and the outcome of patients with squamous cell carcinoma of the supraglottic larynx. J Natl Cancer Inst. 1996; 88:1676-1682.
17. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22:207-219.
18. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients. Breast Cancer Res Treat. 2010; 123:725-731.
19. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009; 13:2236-2252.
20. Swindall AF, Londono-Joshi AI, Schultz MJ, Fineberg N, Buchsbaum DJ, Bellis SL. ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines. Cancer Res. 2013; 73:2368-2378.
21. Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget. 2014; 5:4603-4650. doi:10.18632/oncotarget.2209.
22. Finn RS. Targeting Src in breast cancer. Ann Oncol. 2008; 19:1379-1386.
23. Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumors. Br J Cancer. 2015; 113:365-371.
24. Bolos V, Gasent JM, Lopez-Tarruella S, Grande E. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther. 2010; 3:83-97.
25. Sigbjornsdottir BI, Ragnarsson G, Agnarsson BA, Huiping C, Barkardottir RB, Egilsson V, Ingvarsson S. Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer. J Med Genet. 2000; 37:342-347.
26. Sappino AP, Skalli O, Jackson B, Schurch W, Gabbiani G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int J Cancer. 1988; 41:707-712.
27. Busch S, Acar A, Magnusson Y, Gregersson P, Ryden L, Landberg G. TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer. Oncogene. 2015; 34:27-38.
28. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121:335-348.
29. Dick JE. Stem cell concepts renew cancer research. Blood. 2008; 112:4793-4807.
30. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Onder TT, Wang ZC, Richardson AL, Weinberg RA, Orimo A. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A. 2010; 107:20009-20014.
31. Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas-Jones A, Mokbel K, Mansel RE. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer. 2005; 41:1628-1636.
32. Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, Landberg G, Pahlman S, Jirstrom K. Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res. 2008; 68:9212-9220.
33. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012; 14:22-29.
34. Okroj M, Holmquist E, Nilsson E, Anagnostaki L, Jirstrom K, Blom AM. Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence. Cancer Immunol Immunother. 2015.
35. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, Puntis MC. Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Res. 1995; 55:5043-5048.